Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Veru Inc. VERU
$1.11
-$0.11 (-10.16%)
На 18:00, 12 мая 2023
+2 332.43%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
109314962.00000000
-
week52high
24.55
-
week52low
0.93
-
Revenue
39354352
-
P/E TTM
-1
-
Beta
-0.21730100
-
EPS
-1.34000000
-
Last Dividend
1.04000000
-
Next Earnings Date
11 мая 2023 г. в 12:00
Описание компании
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Brookline Capital | Buy | Buy | 18 мая 2022 г. |
| Jefferies | Buy | Buy | 13 мая 2022 г. |
| Oppenheimer | Outperform | Outperform | 12 апр 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 апр 2022 г. |
| Jefferies | Buy | 13 апр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 дек 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 05 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Eisenberger Mario | A | 85000 | 85000 | 02 ноя 2022 г. |
| Hyun Grace | A | 80000 | 80000 | 02 ноя 2022 г. |
| Lu Lucy | A | 90000 | 90000 | 02 ноя 2022 г. |
| Rankowitz Michael L | A | 95000 | 95000 | 02 ноя 2022 г. |
| STEINER MITCHELL SHUSTER | A | 372000 | 372000 | 02 ноя 2022 г. |
| Greco Michele | A | 102000 | 102000 | 02 ноя 2022 г. |
| BARNETTE K GARY | A | 98000 | 98000 | 02 ноя 2022 г. |
| FISCH HARRY | A | 98000 | 98000 | 02 ноя 2022 г. |
| Eisenberger Mario | D | 0 | 45000 | 15 авг 2022 г. |
| Eisenberger Mario | D | 0 | 100000 | 15 авг 2022 г. |
Новостная лента
Veru Inc. (VERU) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 15:28
Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations & Corporate Communications Mitchell Steiner - Chairman, Chief Executive Officer & President Michele Greco - Chief Financial Officer & Chief Accounting Officer Conference Call Participants Yi Chen - H.C. Wainwright Brandon Folkes - Cantor Fitzgerald Operator Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call.
Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 09:10
Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.18 per share a year ago.
VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates
InvestorPlace
11 мая 2023 г. в 08:09
Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents.
Is a Surprise Coming for Veru (VERU) This Earnings Season?
Zacks Investment Research
09 мая 2023 г. в 13:01
Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
GlobeNewsWire
27 апр 2023 г. в 06:45
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases, today announced it will host a conference call and audio webcast on Thursday, May 11, 2023, at 8:00 a.m. ET to discuss its fiscal 2023 second quarter financial results and provide a business update.